Use of trastuzumab emtansine (T-DM1; K) after pertuzumab plus trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

被引：0
|
作者：
Sanglier, T. [1 ]
Fabi, A. [2 ]
Flores, C. [3 ]
Flahavan, E. [4 ]
Lindegger, N. [5 ]
Montemurro, F. [6 ]
机构：
[1] F Hoffmann La Roche Ltd, RWD Oncol, Basel, Switzerland
[2] Ist Nazl Tumori Regina Elena, Oncol Med, Rome, Italy
[3] Genentech Inc, RWD Oncol, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, RWD Oncol, Welwyn Garden City, Herts, England
[5] F Hoffmann La Roche Ltd, Med Affairs Oncol, Global Prod Dev, Basel, Switzerland
[6] Candiolo Canc Inst, Day Hosp Oncol Multidisciplinare, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [2] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [3] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [4] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [5] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
  • [6] Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients
    Kowalczyk, Lidia
    Bartsch, Rupert
    Singer, Christian F.
    Farr, Alex
    BREAST CARE, 2017, 12 (06) : 401 - 408
  • [7] Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
    Jacot, W.
    Pons, E.
    Guiu, S.
    Levy, C.
    Frenel, J-S
    Bachelot, T.
    D'Hondt, V.
    Firmin, N.
    Romieu, G.
    Thezenas, S.
    Dalenc, F.
    CANCER RESEARCH, 2016, 76
  • [8] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [9] Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.
    Modi, Shanu
    Elias, Anthony D.
    LoRusso, Patricia
    Samant, Meghna
    Guardino, Ellie
    Althaus, Betsy
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
12345